Prostate cancer radiosensitization through poly(ADP-ribose) polymerase-1 hyperactivation

Ying Dong, Erik A. Bey, Long Shan Li, Wareef Kabbani, Jingsheng Yan, Xian Jin Xie, Jer Tsong Hsieh, Jinming Gao, David A. Boothman

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

The clinical experimental agent, β-lapachone (β-lap; Arq 501), can act as a potent radiosensitizer in vitro through an unknown mechanism. In this study, we analyzed the mechanism to determine whether β-lap may warrant clinical evaluation as a radiosensitizer. β-Lap killed prostate cancer cells by NAD(P)H:quinone oxidoreductase 1 (NQO1) metabolic bioactivation, triggering a massive induction of reactive oxygen species, irreversible DNA single-strand breaks (SSB), poly(ADP-ribose) polymerase-1 (PARP-1) hyperactivation, NAD+/ATP depletion, and μ-calpain-induced programmed necrosis. In combination with ionizing radiation (IR), β-lap radiosensitized NQO1+ prostate cancer cells under conditions where nontoxic doses of either agent alone achieved threshold levels of SSBs required for hyperactivation of PARP-1. Combination therapy significantly elevated SSB level, γ-H2AX foci formation, and poly(ADP-ribosylation) of PARP-1, which were associated with ATP loss and induction of μ-calpain-induced programmed cell death. Radiosensitization by β-lap was blocked by the NQO1 inhibitor dicoumarol or the PARP-1 inhibitor DPQ. In a mouse xenograft model of prostate cancer, β-lap synergized with IR to promote antitumor efficacy. NQO1 levels were elevated in ∼60% of human prostate tumors evaluated relative to adjacent normal tissue, where β-lap might be efficacious alone or in combination with radiation. Our findings offer a rationale for the clinical utilization of β-lap (Arq 501) as a radiosensitizer in prostate cancers that overexpress NQO1, offering a potentially synergistic targeting strategy to exploit PARP-1 hyperactivation.

Original languageEnglish (US)
Pages (from-to)8088-8096
Number of pages9
JournalCancer Research
Volume70
Issue number20
DOIs
StatePublished - Oct 15 2010

Fingerprint

Prostatic Neoplasms
Calpain
Ionizing Radiation
NAD
Adenosine Triphosphate
Dicumarol
Single-Stranded DNA Breaks
Heterografts
Adenosine Diphosphate
Prostate
Reactive Oxygen Species
Oxidoreductases
Cell Death
Necrosis
Poly (ADP-Ribose) Polymerase-1
Radiation
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Dong, Y., Bey, E. A., Li, L. S., Kabbani, W., Yan, J., Xie, X. J., ... Boothman, D. A. (2010). Prostate cancer radiosensitization through poly(ADP-ribose) polymerase-1 hyperactivation. Cancer Research, 70(20), 8088-8096. https://doi.org/10.1158/0008-5472.CAN-10-1418

Prostate cancer radiosensitization through poly(ADP-ribose) polymerase-1 hyperactivation. / Dong, Ying; Bey, Erik A.; Li, Long Shan; Kabbani, Wareef; Yan, Jingsheng; Xie, Xian Jin; Hsieh, Jer Tsong; Gao, Jinming; Boothman, David A.

In: Cancer Research, Vol. 70, No. 20, 15.10.2010, p. 8088-8096.

Research output: Contribution to journalArticle

Dong, Ying ; Bey, Erik A. ; Li, Long Shan ; Kabbani, Wareef ; Yan, Jingsheng ; Xie, Xian Jin ; Hsieh, Jer Tsong ; Gao, Jinming ; Boothman, David A. / Prostate cancer radiosensitization through poly(ADP-ribose) polymerase-1 hyperactivation. In: Cancer Research. 2010 ; Vol. 70, No. 20. pp. 8088-8096.
@article{b0c07e1e332f4a16bd72d234efa65bb0,
title = "Prostate cancer radiosensitization through poly(ADP-ribose) polymerase-1 hyperactivation",
abstract = "The clinical experimental agent, β-lapachone (β-lap; Arq 501), can act as a potent radiosensitizer in vitro through an unknown mechanism. In this study, we analyzed the mechanism to determine whether β-lap may warrant clinical evaluation as a radiosensitizer. β-Lap killed prostate cancer cells by NAD(P)H:quinone oxidoreductase 1 (NQO1) metabolic bioactivation, triggering a massive induction of reactive oxygen species, irreversible DNA single-strand breaks (SSB), poly(ADP-ribose) polymerase-1 (PARP-1) hyperactivation, NAD+/ATP depletion, and μ-calpain-induced programmed necrosis. In combination with ionizing radiation (IR), β-lap radiosensitized NQO1+ prostate cancer cells under conditions where nontoxic doses of either agent alone achieved threshold levels of SSBs required for hyperactivation of PARP-1. Combination therapy significantly elevated SSB level, γ-H2AX foci formation, and poly(ADP-ribosylation) of PARP-1, which were associated with ATP loss and induction of μ-calpain-induced programmed cell death. Radiosensitization by β-lap was blocked by the NQO1 inhibitor dicoumarol or the PARP-1 inhibitor DPQ. In a mouse xenograft model of prostate cancer, β-lap synergized with IR to promote antitumor efficacy. NQO1 levels were elevated in ∼60{\%} of human prostate tumors evaluated relative to adjacent normal tissue, where β-lap might be efficacious alone or in combination with radiation. Our findings offer a rationale for the clinical utilization of β-lap (Arq 501) as a radiosensitizer in prostate cancers that overexpress NQO1, offering a potentially synergistic targeting strategy to exploit PARP-1 hyperactivation.",
author = "Ying Dong and Bey, {Erik A.} and Li, {Long Shan} and Wareef Kabbani and Jingsheng Yan and Xie, {Xian Jin} and Hsieh, {Jer Tsong} and Jinming Gao and Boothman, {David A.}",
year = "2010",
month = "10",
day = "15",
doi = "10.1158/0008-5472.CAN-10-1418",
language = "English (US)",
volume = "70",
pages = "8088--8096",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "20",

}

TY - JOUR

T1 - Prostate cancer radiosensitization through poly(ADP-ribose) polymerase-1 hyperactivation

AU - Dong, Ying

AU - Bey, Erik A.

AU - Li, Long Shan

AU - Kabbani, Wareef

AU - Yan, Jingsheng

AU - Xie, Xian Jin

AU - Hsieh, Jer Tsong

AU - Gao, Jinming

AU - Boothman, David A.

PY - 2010/10/15

Y1 - 2010/10/15

N2 - The clinical experimental agent, β-lapachone (β-lap; Arq 501), can act as a potent radiosensitizer in vitro through an unknown mechanism. In this study, we analyzed the mechanism to determine whether β-lap may warrant clinical evaluation as a radiosensitizer. β-Lap killed prostate cancer cells by NAD(P)H:quinone oxidoreductase 1 (NQO1) metabolic bioactivation, triggering a massive induction of reactive oxygen species, irreversible DNA single-strand breaks (SSB), poly(ADP-ribose) polymerase-1 (PARP-1) hyperactivation, NAD+/ATP depletion, and μ-calpain-induced programmed necrosis. In combination with ionizing radiation (IR), β-lap radiosensitized NQO1+ prostate cancer cells under conditions where nontoxic doses of either agent alone achieved threshold levels of SSBs required for hyperactivation of PARP-1. Combination therapy significantly elevated SSB level, γ-H2AX foci formation, and poly(ADP-ribosylation) of PARP-1, which were associated with ATP loss and induction of μ-calpain-induced programmed cell death. Radiosensitization by β-lap was blocked by the NQO1 inhibitor dicoumarol or the PARP-1 inhibitor DPQ. In a mouse xenograft model of prostate cancer, β-lap synergized with IR to promote antitumor efficacy. NQO1 levels were elevated in ∼60% of human prostate tumors evaluated relative to adjacent normal tissue, where β-lap might be efficacious alone or in combination with radiation. Our findings offer a rationale for the clinical utilization of β-lap (Arq 501) as a radiosensitizer in prostate cancers that overexpress NQO1, offering a potentially synergistic targeting strategy to exploit PARP-1 hyperactivation.

AB - The clinical experimental agent, β-lapachone (β-lap; Arq 501), can act as a potent radiosensitizer in vitro through an unknown mechanism. In this study, we analyzed the mechanism to determine whether β-lap may warrant clinical evaluation as a radiosensitizer. β-Lap killed prostate cancer cells by NAD(P)H:quinone oxidoreductase 1 (NQO1) metabolic bioactivation, triggering a massive induction of reactive oxygen species, irreversible DNA single-strand breaks (SSB), poly(ADP-ribose) polymerase-1 (PARP-1) hyperactivation, NAD+/ATP depletion, and μ-calpain-induced programmed necrosis. In combination with ionizing radiation (IR), β-lap radiosensitized NQO1+ prostate cancer cells under conditions where nontoxic doses of either agent alone achieved threshold levels of SSBs required for hyperactivation of PARP-1. Combination therapy significantly elevated SSB level, γ-H2AX foci formation, and poly(ADP-ribosylation) of PARP-1, which were associated with ATP loss and induction of μ-calpain-induced programmed cell death. Radiosensitization by β-lap was blocked by the NQO1 inhibitor dicoumarol or the PARP-1 inhibitor DPQ. In a mouse xenograft model of prostate cancer, β-lap synergized with IR to promote antitumor efficacy. NQO1 levels were elevated in ∼60% of human prostate tumors evaluated relative to adjacent normal tissue, where β-lap might be efficacious alone or in combination with radiation. Our findings offer a rationale for the clinical utilization of β-lap (Arq 501) as a radiosensitizer in prostate cancers that overexpress NQO1, offering a potentially synergistic targeting strategy to exploit PARP-1 hyperactivation.

UR - http://www.scopus.com/inward/record.url?scp=78049311247&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78049311247&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-10-1418

DO - 10.1158/0008-5472.CAN-10-1418

M3 - Article

C2 - 20940411

AN - SCOPUS:78049311247

VL - 70

SP - 8088

EP - 8096

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 20

ER -